Cardiff Oncology, Inc. (CRDF)
CRDF Stock Price Chart
Explore Cardiff Oncology, Inc. interactive price chart. Choose custom timeframes to analyze CRDF price movements and trends.
CRDF Company Profile
Discover essential business fundamentals and corporate details for Cardiff Oncology, Inc. (CRDF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
27 Jul 2004
Employees
32.00
Website
https://www.cardiffoncology.comCEO
Mark Erlander
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
CRDF Financial Timeline
Browse a chronological timeline of Cardiff Oncology, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.20.
Earnings released on 29 Jul 2025
EPS came in at -$0.21 falling short of the estimated -$0.19 by -10.53%, while revenue for the quarter reached $121.00K , beating expectations by +10.63%.
Earnings released on 8 May 2025
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%, while revenue for the quarter reached $109.00K , beating expectations by +22.07%.
Earnings released on 27 Feb 2025
EPS came in at -$0.21 surpassing the estimated -$0.26 by +19.23%, while revenue for the quarter reached $151.00K , beating expectations by +60.35%.
Earnings released on 7 Nov 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $165.00K , beating expectations by +135.71%.
Earnings released on 8 Aug 2024
EPS came in at -$0.26 falling short of the estimated -$0.25 by -4.00%, while revenue for the quarter reached $163.00K , beating expectations by +171.67%.
Earnings released on 2 May 2024
EPS came in at -$0.22 surpassing the estimated -$0.25 by +12.00%, while revenue for the quarter reached $205.00K , beating expectations by +192.86%.
Earnings released on 29 Feb 2024
EPS came in at -$0.21 surpassing the estimated -$0.26 by +19.23%, while revenue for the quarter reached $156.00K , beating expectations by +290.00%.
Earnings released on 2 Nov 2023
EPS came in at -$0.22 surpassing the estimated -$0.29 by +24.14%, while revenue for the quarter reached $141.00K , beating expectations by +252.50%.
Earnings released on 9 Aug 2023
EPS came in at -$0.25 surpassing the estimated -$0.27 by +7.41%, while revenue for the quarter reached $108.00K , beating expectations by +170.00%.
Earnings released on 4 May 2023
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%, while revenue for the quarter reached $83.00K , beating expectations by +38.33%.
Earnings released on 2 Mar 2023
EPS came in at -$0.20 surpassing the estimated -$0.25 by +20.00%, while revenue for the quarter reached $128.00K , beating expectations by +74.74%.
Earnings released on 3 Nov 2022
EPS came in at -$0.20 surpassing the estimated -$0.27 by +25.93%, while revenue for the quarter reached $93.00K , beating expectations by +36.36%.
Earnings released on 4 Aug 2022
EPS came in at -$0.24 surpassing the estimated -$0.25 by +4.00%, while revenue for the quarter reached $91.00K , missing expectations by -2.15%.
Earnings released on 5 May 2022
EPS came in at -$0.25 falling short of the estimated -$0.23 by -8.70%, while revenue for the quarter reached $74.00K , beating expectations by +30.74%.
Earnings released on 24 Feb 2022
EPS came in at -$0.23 falling short of the estimated -$0.17 by -35.29%, while revenue for the quarter reached $133.00K , beating expectations by +224.39%.
Earnings released on 4 Nov 2021
EPS came in at -$0.17 matching the estimated -$0.17, while revenue for the quarter reached $86.00K , beating expectations by +186.67%.
Earnings released on 5 Aug 2021
EPS came in at -$0.17 falling short of the estimated -$0.15 by -13.33%, while revenue for the quarter reached $68.00K , missing expectations by -54.67%.
Earnings released on 6 May 2021
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $72.00K , missing expectations by -52.00%.
Earnings released on 25 Feb 2021
EPS came in at -$0.19 falling short of the estimated -$0.15 by -26.67%, while revenue for the quarter reached $119.26K , beating expectations by +297.52%.
Earnings released on 5 Nov 2020
EPS came in at -$0.19 surpassing the estimated -$0.20 by +5.00%, while revenue for the quarter reached $136.40K , meeting expectations.
CRDF Stock Performance
Access detailed CRDF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.